MC2 THERAPEUTICS LIMITED
Get an alert when MC2 THERAPEUTICS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£940K
-43.5% vs 2023
Net assets
-£4M
-5,614.6% vs 2023
Employees
14
0% vs 2023
Profit before tax
-£4.8M
+10.5% vs 2023
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Negative shareholders' funds
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · Δ = latest vs prior filed period · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | Δ vs prior |
|---|---|---|---|---|
| Turnover | £18,245,019 | £15,730,799 | -13.8% | |
| Operating profit | -£5,015,584 | -£4,255,243 | +15.2% | |
| Profit before tax | -£5,362,616 | -£4,797,504 | +10.5% | |
| Net profit | -£4,662,616 | -£3,966,184 | +14.9% | |
| Cash | £1,664,335 | £940,424 | -43.5% | |
| Total assets less current liabilities | -£70,641 | -£4,036,825 | -5,614.6% | |
| Net assets | -£70,641 | -£4,036,825 | -5,614.6% | |
| Equity | -£70,641 | -£4,036,825 | -5,614.6% | |
| Average employees | 14 | 14 | 0% | |
| Wages | £541,429 | £599,015 | +10.6% | |
| Directors' remuneration | — | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | -27.5% | -27.1% | |
| Net margin | -25.6% | -25.2% | |
| Current ratio | 0.88x | 0.71x | |
| Interest cover | -12.05x | -7.33x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- MC2 THERAPEUTICS LIMITED 2019-02-05 → present
- DRUG DELIVERY SOLUTIONS LIMITED 2005-02-01 → 2019-02-05
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- RSM UK Audit LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Based on the directors' assessment they consider that there is sufficient working capital for the company to continue for a period of at least 12 months from the date of signing of the financial statements and therefore it is appropriate to prepare the financial statements on a going concern basis.”
Group structure
- MC2 THERAPEUTICS LIMITED · parent
- Disperse Pharma Limited 100%
- MC2 Therapeutics PTY LTD 100%
Significant events
- “Subsequent to year-end 2024, MC2 Therapeutics has entered into agreements with partners in Australia and Canada to further strengthening the global roll-out of Wynzora® Cream.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
4 active · 12 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| HILTON, Tim | Secretary | 2024-12-19 | — | — |
| AHLGREEN, Trine | Director | 2026-01-27 | Aug 1975 | Danish |
| HARRISON, Christopher Neil | Director | 2025-12-18 | Nov 1971 | British |
| MIKKELSEN, Tomas Dahl | Director | 2022-12-22 | May 1980 | Danish |
Show 12 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| TWYDELL, Richard William | Secretary | 2005-02-01 | 2024-12-19 |
| BUDOLFSEN, Elsebeth | Director | 2005-11-04 | 2009-11-01 |
| CLAUSEN, Anette Merete Nohr | Director | 2005-07-12 | 2018-11-13 |
| CLAUSEN, Mads Jorgen Nohr | Director | 2008-06-25 | 2026-01-31 |
| CRUTCHLEY, Nigel, Dr | Director | 2018-11-13 | 2023-03-13 |
| LANGE, Jesper Jorn | Director | 2008-06-25 | 2022-12-22 |
| LENON, Stephen John, Dr | Director | 2005-02-01 | 2022-12-29 |
| PRAESTEGAARD, Morten | Director | 2018-11-13 | 2022-12-22 |
| PRIMROSE, Kenneth Mark | Director | 2005-11-04 | 2007-03-01 |
| SINDET PEDERSEN, Steen, Professor | Director | 2005-07-12 | 2012-12-31 |
| TWYDELL, Richard William | Director | 2005-02-01 | 2018-11-13 |
| WHEELER, Derek Alfred | Director | 2005-07-12 | 2018-11-13 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Mc2 Therapeutics A/S | Corporate entity | Shares 75–100% | 2016-04-06 | Active |
Filing timeline
Last 20 of 120 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-02-11 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2026-02-06 | TM01 | officers | Termination director company with name termination date | |
| 2026-01-27 | AP01 | officers | Appoint person director company with name date | |
| 2025-12-18 | AP01 | officers | Appoint person director company with name date | |
| 2025-10-24 | PSC05 | persons-with-significant-control | Change to a person with significant control | |
| 2025-10-06 | AA | accounts | Accounts with accounts type full | |
| 2025-02-04 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-01-07 | AP03 | officers | Appoint person secretary company with name date | |
| 2025-01-07 | TM02 | officers | Termination secretary company with name termination date | |
| 2024-09-28 | AA | accounts | Accounts with accounts type small | |
| 2024-02-13 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2023-12-21 | SH01 | capital | Capital allotment shares | |
| 2023-09-26 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2023-08-02 | AA | accounts | Accounts with accounts type small | |
| 2023-03-13 | TM01 | officers | Termination director company with name termination date | |
| 2023-02-03 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2022-12-29 | TM01 | officers | Termination director company with name termination date | |
| 2022-12-23 | SH01 | capital | Capital allotment shares | |
| 2022-12-22 | CH01 | officers | Change person director company with change date | |
| 2022-12-22 | TM01 | officers | Termination director company with name termination date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 6
- Capital events
- 0
- Officers appointed
- 2
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.